-
What About a Latent Cure Model? Assessing Cure Models’ Performance in Pediatric Acute Lymphoblastic Leukemia Treated With Tisagenlecleucel
Sep 9, 2025, 16:22 PM -
Costs Associated With the Administration, Postinfusion Monitoring, and Management of Adverse Events (AEs) Related to Novel Drugs for Second-Line (2L+) Treatment of Small-Cell Lung Cancer (SCLC)
Sep 9, 2025, 16:22 PM -
Development of a Multidimensional HTA Evaluation for the Introduction of Clesrovimab in Pediatric RSV Prevention: An Integrated Methodological Approach
Sep 9, 2025, 16:22 PM -
Forecasting the Rise in Direct and Indirect Costs for Lung Cancer on the Example of Poland
Sep 9, 2025, 16:22 PM -
Eliciting Patients' and Clinicians' Preferences on Adjuvant Treatment for HR+/HER2- Early Breast Cancer: Design of a Probabilistic Threshold Technique in Italy
Sep 9, 2025, 16:22 PM -
Development of an LLM-Based Computable Phenotype for Pediatric Lymphoma Subtypes Using Structured and Unstructured Electronic Medical Record Data
Sep 9, 2025, 16:22 PM -
Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) in India: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Social Inequality in the Uptake of Varicella Vaccination: A Danish Nationwide Observational Study
Sep 9, 2025, 16:22 PM -
Comorbidities As a Risk Predictor of Kidney Disease Progression Among Patients Diagnosed With Chronic Kidney Disease
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model
Sep 9, 2025, 16:22 PM -
Budget Impact of an Organized Screening Program for Chronic Kidney Disease in High-Risk Populations in France
Sep 9, 2025, 16:22 PM -
Characterizing Polycystic Ovary Syndrome (PCOS) and Related Diagnoses Using a Large US Electronic Health Records Database Linked to Claims, 2020-2025
Sep 9, 2025, 16:22 PM -
BHM and BHM-Based Extrapolations in an HTA Framework
Sep 9, 2025, 16:22 PM -
Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany
Sep 9, 2025, 16:22 PM -
Evolution of Acceptance of Evidence and PMA Outcomes by HTA Authorities for ATMPs in the EU4 and the UK 2017-2025
Sep 9, 2025, 16:22 PM -
The Role of Health-Related Quality of Life in German HTA Decisions: An Analysis of G-BA Assessments From 2020-2024
Sep 9, 2025, 16:22 PM -
Healthcare Pathway of a Large Cohort of Patients With Chronic Obstructive Pulmonary Disease During the Last Year of Life
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and France: Lessons for Poland
Sep 9, 2025, 16:22 PM -
Implications of Recent US Policy Changes on Evidence Generation Requirements for Enabling Access to Medicines and Vaccines in Low- and Middle-Income Countries
Sep 9, 2025, 16:22 PM -
Reimbursement Trends for GLP-1s and Emerging Antiobesity Drugs Across Seven Global Markets
Sep 9, 2025, 16:22 PM
